GlobalData on MSN7h
Regeneron’s macular oedema therapy shows promise in Phase III trial
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
manilatimes10h
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...
Ace ICSE 2025 Biology Exam With Last Minute Suggestions From Expert- Check Important Topics to Cover
With the ICSE 2025 exams right around the corner, let’s take a look at the ICSE Class 10 Biology paper. Preparing for the ...
IPPMEDIA13h
SPECIAL REPORT: Thriving through climate change: Electricity, charcoal dilemma - 1
Public sensitization on the essence of using electricity as the primary cooking energy source is highly needed to discourage ...